2018 Q1 Sentiment Esperion Therapeutics Inc (NASDAQ:ESPR)

September 8, 2018 - By Robert Shackelford

Sentiment for Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics Inc (NASDAQ:ESPR) institutional sentiment increased to 1.5 in Q1 2018. Its up 0.17, from 1.33 in 2017Q4. The ratio has improved, as 90 funds opened new or increased stock positions, while 60 sold and reduced their equity positions in Esperion Therapeutics Inc. The funds in our partner’s database now have: 24.56 million shares, up from 22.69 million shares in 2017Q4. Also, the number of funds holding Esperion Therapeutics Inc in their top 10 stock positions decreased from 6 to 4 for a decrease of 2. Sold All: 14 Reduced: 46 Increased: 54 New Position: 36.

Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol . The company has market cap of $1.35 billion. The Company’s lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. It currently has negative earnings.

The stock increased 0.76% or $0.38 during the last trading session, reaching $50.18. About 344,196 shares traded. Esperion Therapeutics, Inc. (NASDAQ:ESPR) has risen 12.80% since September 8, 2017 and is uptrending. It has outperformed by 0.23% the S&P500.

Analysts await Esperion Therapeutics, Inc. (NASDAQ:ESPR) to report earnings on November, 6. They expect $-1.60 EPS, up 13.98 % or $0.26 from last year’s $-1.86 per share. After $-1.71 actual EPS reported by Esperion Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -6.43 % EPS growth.

Meditor Group Ltd holds 29.46% of its portfolio in Esperion Therapeutics, Inc. for 2.59 million shares. Bb Biotech Ag owns 2.41 million shares or 4.82% of their US portfolio. Moreover, Iguana Healthcare Management Llc has 4.76% invested in the company for 100,000 shares. The Sweden-based Rhenman & Partners Asset Management Ab has invested 2.18% in the stock. Partner Fund Management L.P., a California-based fund reported 1.13 million shares.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Ratings Coverage

Ratings analysis reveals 55% of Esperion’s analysts are positive. Out of 11 Wall Street analysts rating Esperion, 6 give it “Buy”, 3 “Sell” rating, while 2 recommend “Hold”. The lowest target is $4100 while the high is $15300. The stock’s average target of $88.30 is 75.97% above today’s ($50.18) share price. ESPR was included in 12 notes of analysts from March 19, 2018. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) earned “Buy” rating by Jefferies on Monday, March 19. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Neutral” rating given on Tuesday, March 27 by Chardan Capital Markets. The rating was downgraded by J.P. Morgan to “Sell” on Thursday, May 3. The company was maintained on Thursday, May 3 by Deutsche Bank. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Underweight” rating given on Thursday, May 3 by JP Morgan. Northland Capital maintained Esperion Therapeutics, Inc. (NASDAQ:ESPR) rating on Thursday, April 19. Northland Capital has “Buy” rating and $12100 target. The rating was maintained by Credit Suisse with “Outperform” on Friday, May 4. The stock has “Buy” rating by Cowen & Co on Tuesday, March 27. The stock of Esperion Therapeutics, Inc. (NASDAQ:ESPR) has “Buy” rating given on Wednesday, May 2 by JMP Securities. The firm earned “Buy” rating on Friday, August 17 by Citigroup.

More notable recent Esperion Therapeutics, Inc. (NASDAQ:ESPR) news were published by: Nasdaq.com which released: “Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)” on August 10, 2018, also Nasdaq.com with their article: “Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety Study of …” published on August 25, 2018, Nasdaq.com published: “Market Trends Toward New Normal in Esperion Therapeutics, Oxford Immunotec Global, Limoneira, R1 RCM …” on August 20, 2018. More interesting news about Esperion Therapeutics, Inc. (NASDAQ:ESPR) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on August 17, 2018 as well as Fool.com‘s news article titled: “3 Biotech Stocks That Could Soar in September” with publication date: September 02, 2018.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.